Merck's top immunology drugs face biosimilar competition. The $1.85 billion acquisition of Pandion Therapeutics gives the pharma giant an opportunity to build up its immunology pipeline with a new approach to treating autoimmune disorders.
Despite continued economic impacts from the Covid-19 pandemic, biotechnology companies and VC firms raised significant amounts of funding this week. For example, Massachusetts-based Pandion Therapeutics closed $80 million in funding to develop a therapeutic designed to treat autoimmune diseases.
This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.